var data={"title":"Pulmonary hypertension in hemodialysis patients","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pulmonary hypertension in hemodialysis patients</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">William Hopkins, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">Thomas A Golper, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">Gerald A Beathard, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">Jeffrey S Berns, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">David L Cull, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">Alice M Sheridan, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">Kathryn A Collins, MD, PhD, FACS</a></dd><dd><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 12, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H111099120\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dialysis patients, particularly those on hemodialysis, are at risk for development of or worsening of pre-existing pulmonary hypertension (PH). Although multifactorial, the increased risk is due, in part, to the presence of an arteriovenous (AV) access.</p><p>PH among dialysis patents is presented in this topic review. The evaluation and management of AV fistula-associated heart failure and other complications of hemodialysis AV access are presented separately. (See <a href=\"topic.htm?path=evaluation-and-management-of-heart-failure-caused-by-hemodialysis-arteriovenous-access\" class=\"medical medical_review\">&quot;Evaluation and management of heart failure caused by hemodialysis arteriovenous access&quot;</a> and <a href=\"topic.htm?path=arteriovenous-fistula-creation-for-hemodialysis-and-its-complications#H4266850144\" class=\"medical medical_review\">&quot;Arteriovenous fistula creation for hemodialysis and its complications&quot;, section on 'Complications of AV fistula placement'</a> and <a href=\"topic.htm?path=arteriovenous-graft-creation-for-hemodialysis-and-its-complications#H1460532473\" class=\"medical medical_review\">&quot;Arteriovenous graft creation for hemodialysis and its complications&quot;, section on 'Complications of AV graft placement'</a>.)</p><p class=\"headingAnchor\" id=\"H3715598996\"><span class=\"h1\">DEFINITION AND CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PH is defined as an elevated mean arterial pressure &ge;25 mmHg at rest [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/1\" class=\"abstract_t\">1</a>]. PH is classified into the five groups given in the table (<a href=\"image.htm?imageKey=PULM%2F66348\" class=\"graphic graphic_table graphicRef66348 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Patients with end-stage renal disease (ESRD) are considered to have group 5 PH, which refers to PH of unclear or multifactorial mechanism (<a href=\"image.htm?imageKey=PULM%2F66348\" class=\"graphic graphic_table graphicRef66348 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/1\" class=\"abstract_t\">1</a>]. However, some ESRD patients may also have PH from heart failure (group 2) or chronic lung disease (group 3). (See <a href=\"topic.htm?path=classification-and-prognosis-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">&quot;Classification and prognosis of pulmonary hypertension in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4235246744\"><span class=\"h1\">EPIDEMIOLOGY AND RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reported prevalence of PH among dialysis patients has ranged from less than 10 percent to over 50 percent [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/3-16\" class=\"abstract_t\">3-16</a>]. The wide range primarily relates to the technique used to diagnose PH <span class=\"nowrap\">(echo/Doppler</span> versus catheterization), the variability in diagnostic criteria, and the presence or absence of symptoms [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/15\" class=\"abstract_t\">15</a>]. In the only study in which the PH diagnosis was based on right-sided cardiac catheterization (the gold standard), all patients were selected for study based upon presence of unexplained dyspnea [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/16\" class=\"abstract_t\">16</a>]. In this study, PH was present in 81 percent of hemodialysis patients and in 77 percent of nondialysis chronic kidney disease (CKD) patients. The mean pulmonary arterial pressure was higher in the patients on dialysis compared with the patients who were not on dialysis (42 versus 35 mmHg).</p><p>The risk appears to be higher among hemodialysis compared with peritoneal dialysis patients. In the four studies that directly compared hemodialysis patients with peritoneal dialysis patients, PH was higher in hemodialysis patients (19 to 59 percent versus &lt;19 percent) [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/6,12-14\" class=\"abstract_t\">6,12-14</a>].</p><p class=\"headingAnchor\" id=\"H2691105011\"><span class=\"h2\">Dialysis-specific risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major dialysis-specific risk factor among hemodialysis patients is the arteriovenous (AV) access (AV fistula or AV graft), particularly if the flow in the access increases over time. Studies have shown that the severity of PH directly correlates with duration of the AV access and the flow through it [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/4,6,17-24\" class=\"abstract_t\">4,6,17-24</a>].</p><p>Other dialysis-specific factors include hypervolemia, left ventricular dysfunction, and hypoalbuminemia [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/11,15\" class=\"abstract_t\">11,15</a>].</p><p class=\"headingAnchor\" id=\"H686883394\"><span class=\"h1\">PATHOGENESIS IN END-STAGE RENAL DISEASE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanisms that underlie the development of PH in patients with chronic kidney disease (CKD) with or without an arteriovenous (AV) access are unknown and poorly studied.</p><p>Several mechanisms have been proposed, the most logical of which is that PH in this population may relate to increased flow through the pulmonary vascular bed from chronic volume overload (from CKD itself) and increased venous return (from AV access). Evidence to support this theory is derived from the known hemodynamic effects increased flow through the pulmonary bed and the known hemodynamic effects of AV <span class=\"nowrap\">fistula/grafts</span> (eg, decreased systemic vascular resistance, enhanced venous return, and increased cardiac output). However, the development of PH in this setting most likely presumes a stiff left ventricle and the development of postcapillary PH (ie, pulmonary venous hypertension) (<a href=\"image.htm?imageKey=PULM%2F105764\" class=\"graphic graphic_table graphicRef105764 \">table 2</a>). This is because, in patients with a normal or near-normal left heart filling pressure and normal kidney function, increased cardiac output and pulmonary blood flow due to an acquired AV shunt or traumatic peripheral fistula are generally not sufficient on their own to cause PH, since the pulmonary vasculature typically accommodates the increased flow with little or no increase in the pulmonary artery pressure. By contrast, in the setting of a stiff left ventricle, increased venous return from increased flow through the AV access markedly increases left ventricular diastolic, left atrial, pulmonary venous, and pulmonary capillary pressures, thereby predisposing patients to the development of PH. (See <a href=\"topic.htm?path=pulmonary-hypertension-in-patients-with-left-heart-failure#H2011484501\" class=\"medical medical_review\">&quot;Pulmonary hypertension in patients with left heart failure&quot;, section on 'Pathogenesis'</a> and <a href=\"topic.htm?path=classification-and-prognosis-of-pulmonary-hypertension-in-adults#H5\" class=\"medical medical_review\">&quot;Classification and prognosis of pulmonary hypertension in adults&quot;, section on 'Group 2 PH (left heart disease)'</a>.)</p><p>However, this is not the only mechanism likely to be at play. Other factors that have been cited, but do not have a well-understood role, include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreases in the vasodilator nitric oxide (NO), which are common in patients with CKD [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/25-28\" class=\"abstract_t\">25-28</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/29\" class=\"abstract_t\">29</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary vascular calcification [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/30,31\" class=\"abstract_t\">30,31</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neutrophil activation related to exposure to bioincompatible dialysis membranes [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/32\" class=\"abstract_t\">32</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent embolization from repeated AV access thrombectomies [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/33-35\" class=\"abstract_t\">33-35</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nocturnal hypoxemia [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/36,37\" class=\"abstract_t\">36,37</a>]</p><p/><p>Similar to other forms of PH, PH in patients with CKD is progressive, and, while PH may initially be reversible, at some point, PH may become irreversible. This is supported by the observation that, in some patients who undergo kidney transplantation, PH resolves, as well as the observation that pulmonary pressures can normalize when flow through the AV <span class=\"nowrap\">fistula/graft</span> is reduced. (See <a href=\"#H1580786084\" class=\"local\">'Access management'</a> below and <a href=\"#H3747593179\" class=\"local\">'Diagnosis'</a> below and <a href=\"#H3868930531\" class=\"local\">'Prognosis'</a> below.)</p><p>Whether mechanisms similar to those involved in the pathogenesis of other forms of PH are also involved in PH associated with CKD is unknown. (See <a href=\"topic.htm?path=the-epidemiology-and-pathogenesis-of-pulmonary-arterial-hypertension-group-1#H4\" class=\"medical medical_review\">&quot;The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)&quot;, section on 'Pathogenetic mechanisms'</a> and <a href=\"topic.htm?path=pulmonary-hypertension-in-patients-with-left-heart-failure\" class=\"medical medical_review\">&quot;Pulmonary hypertension in patients with left heart failure&quot;</a> and <a href=\"topic.htm?path=pulmonary-hypertension-due-to-lung-disease-and-or-hypoxemia-group-3-pulmonary-hypertension-epidemiology-pathogenesis-and-diagnostic-evaluation-in-adults#H2\" class=\"medical medical_review\">&quot;Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults&quot;, section on 'Pathogenesis'</a> and <a href=\"topic.htm?path=pulmonary-arterial-hypertension-associated-with-human-immunodeficiency-virus#H4\" class=\"medical medical_review\">&quot;Pulmonary arterial hypertension associated with human immunodeficiency virus&quot;, section on 'Pathogenesis'</a> and <a href=\"topic.htm?path=epidemiology-pathogenesis-clinical-evaluation-and-diagnosis-of-pulmonary-veno-occlusive-disease-in-adults#H4\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease in adults&quot;, section on 'Pathogenesis and risk factors'</a>.)</p><p class=\"headingAnchor\" id=\"H1861623073\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The symptoms and signs of PH are the same as in those without chronic kidney disease (CKD). The most common symptoms of PH are dyspnea with exertion and the signs and symptoms of right heart failure. Less commonly, patients present with exertional chest pain, exertional syncope, and gastrointestinal complaints due to liver congestion. The symptoms and signs of PH are discussed in detail separately. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-pulmonary-hypertension-in-adults#H17914458\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of pulmonary hypertension in adults&quot;, section on 'Clinical manifestations'</a>.)</p><p class=\"headingAnchor\" id=\"H2374946375\"><span class=\"h1\">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS IN DIALYSIS PATIENTS</span></p><p class=\"headingAnchor\" id=\"H1584569684\"><span class=\"h2\">Suspecting PH in patients with ESRD</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of PH is difficult among end-stage renal disease (ESRD) patients because such patients commonly have dyspnea and edema related to volume overload. It should be suspected in those who develop worsening symptoms after arteriovenous (AV) access placement.</p><p>Typically, the first step in management as well as diagnosis is reducing dry weight in an effort to relieve symptoms. (See <a href=\"#H3142051344\" class=\"local\">'Dialysis management'</a> below.)</p><p>Some patients do not tolerate ultrafiltration and should be further evaluated. The differential diagnosis of dyspnea and intradialytic hemodynamic instability includes heart failure, cardiomegaly, or ischemic heart disease. This evaluation typically includes an echocardiogram (See <a href=\"topic.htm?path=intradialytic-hypotension-in-an-otherwise-stable-patient#H6717508\" class=\"medical medical_review\">&quot;Intradialytic hypotension in an otherwise stable patient&quot;, section on 'Second-line approach'</a>.)</p><p>A diagnosis of PH should also be seriously considered in patients who have persistent dyspnea and edema despite achieving euvolemia; an echocardiogram is appropriate in such patients.</p><p class=\"headingAnchor\" id=\"H3747593179\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with suspected PH should be evaluated by a clinician with expertise in PH. The evaluation and diagnosis of PH in patients with ESRD are similar to other patients without ESRD. It typically begins with an echocardiogram and ruling out other causes of PH. The gold standard for the diagnosis of PH is the demonstration of an elevated mean pulmonary artery pressure &ge;25 mmHg on right heart catheterization (RHC). (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-pulmonary-hypertension-in-adults#H3\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of pulmonary hypertension in adults&quot;, section on 'Diagnostic evaluation'</a>.)</p><p>Among patients with AV access who are newly diagnosed with PH or who have worsening of PH, the contribution of the AV access can be initially assessed by manually compressing the AV access for one minute, while measuring pulmonary hemodynamics on RHC. There may be some concern that such compression will lead to thrombosis of the access, particularly if the access is an AV graft; however, in practice, it is much harder to thrombose an AV access with manual compression that one would expect. In an effort to establish the diagnosis of PH, we do not hesitate to perform this maneuver.</p><p>If a significant component of the patient's PH is related to the AV access, the mean pulmonary artery pressure, right atrial pressure, and pulmonary vascular resistance will normalize or significantly decrease when the AV access is compressed. However, the definition of what constitutes a significant decrease is not established and is highly subjective [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/6,24\" class=\"abstract_t\">6,24</a>]. (See <a href=\"topic.htm?path=pulmonary-artery-catheterization-interpretation-of-hemodynamic-values-and-waveforms-in-adults\" class=\"medical medical_review\">&quot;Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults&quot;</a>.)</p><p>Among those with ESRD in whom an AV access is proposed, there are no clinical or RHC features that determine the development of or worsening of pre-existing PH with worsen future AV access placement.</p><p class=\"headingAnchor\" id=\"H372974248\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with PH should be comanaged with a clinician with expertise in PH.</p><p class=\"headingAnchor\" id=\"H518583624\"><span class=\"h2\">Dialysis modality in preexisting PH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with pre-existing, symptomatic PH who are being considered for maintenance dialysis, we suggest evaluation for peritoneal dialysis preferentially over hemodialysis. Even mildly symptomatic PH may worsen subsequent to arteriovenous (AV) access creation. Peritoneal dialysis obviates the need for AV access. In addition, peritoneal dialysis provides daily ultrafiltration that may prevent worsening of symptoms with interdialytic volume overload. However, among some patients with primary lung disease, peritoneal dialysis may decrease vital capacity, particularly at night if performing continuous cycler peritoneal dialysis. In addition, there are often multiple other reasons that a patient may not be able or willing to perform peritoneal dialysis. Patients should be individually evaluated. (See <a href=\"topic.htm?path=choosing-a-modality-for-chronic-peritoneal-dialysis#H2\" class=\"medical medical_review\">&quot;Choosing a modality for chronic peritoneal dialysis&quot;, section on 'Types of peritoneal dialysis'</a>.)</p><p>For those who are not candidates for peritoneal dialysis because of comorbidities or other reasons, we suggest a tunneled catheter, rather than an AV access, for the reasons described above (see <a href=\"#H686883394\" class=\"local\">'Pathogenesis in end-stage renal disease'</a> above). In addition, daily dialysis (home or in center) may provide a benefit because it minimizes volume accumulation. (See <a href=\"#H686883394\" class=\"local\">'Pathogenesis in end-stage renal disease'</a> above and <a href=\"topic.htm?path=dialysis-modality-and-patient-outcome#H2\" class=\"medical medical_review\">&quot;Dialysis modality and patient outcome&quot;, section on 'Selection of dialysis modality'</a>.)</p><p>If the patient is not a candidate for peritoneal dialysis and a tunneled catheter is not plausible, an AV access based off a small artery (eg, radiocephalic fistula) is a reasonable alternative but will require vigilant monitoring. (See <a href=\"topic.htm?path=overview-of-chronic-hemodialysis-vascular-access\" class=\"medical medical_review\">&quot;Overview of chronic hemodialysis vascular access&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H874504879\"><span class=\"h2\">Monitoring for PH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with known PH should be monitored for development of or worsening of symptoms of PH after initiating dialysis and particularly after creation of an AV access. As an example, those with known PH and dyspnea that does not improve or progresses despite dialysis or aggressive ultrafiltration may need further evaluation with another echocardiogram <span class=\"nowrap\">and/or</span> a right heart catheterization (RHC) to evaluate for progressive disease.</p><p>In addition, for those who have an AV access, compression of the AV graft or fistula during RHC can determine the contribution of the access to the patients PH. (See <a href=\"#H2374946375\" class=\"local\">'Diagnosis and differential diagnosis in dialysis patients'</a> above.)</p><p>An <span class=\"nowrap\">ultrasound/Doppler</span> should also be obtained to determine whether the flow through the AV <span class=\"nowrap\">fistula/graft</span> is too high. (See <a href=\"#H1580786084\" class=\"local\">'Access management'</a> below.)</p><p>Among patients with pre-existing PH who do not worsen after dialysis or AV access placement, we typically obtain an echocardiogram every three months to reassess heart size, function, and pulmonary hemodynamics, although the value of this approach is unproven.</p><p class=\"headingAnchor\" id=\"H3325684074\"><span class=\"h2\">Treatment of symptomatic patients</span></p><p class=\"headingAnchor\" id=\"H3142051344\"><span class=\"h3\">Dialysis management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All dialysis patients with significant PH should be managed with aggressive removal of volume. The estimated dry weight should be maintained as low as possible without causing intra- or interdialytic hypotension. This may require changes in the dialysis prescription to provide longer or more frequent dialysis sessions in order to safely achieve a lower dry weight. (See <a href=\"topic.htm?path=intradialytic-hypotension-in-an-otherwise-stable-patient#H715661805\" class=\"medical medical_review\">&quot;Intradialytic hypotension in an otherwise stable patient&quot;, section on 'Prevention of recurrent episodes'</a>.)</p><p class=\"headingAnchor\" id=\"H1580786084\"><span class=\"h3\">Access management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If symptoms such as severe dyspnea or edema persist despite aggressive ultrafiltration, we evaluate the AV access blood flow. If the blood flow is higher than that minimally required for hemodialysis access (ie, approximately 500 <span class=\"nowrap\">mL/min</span> [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/38\" class=\"abstract_t\">38</a>]), flow reduction (eg, banding) should be undertaken. Pulmonary pressures may decrease following ligation of the AV fistula [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/23,33\" class=\"abstract_t\">23,33</a>].</p><p>If symptoms do not improve after flow reduction, we ligate the fistula and transition patients to peritoneal dialysis, if appropriate, or place a tunneled catheter for those who are not candidates for peritoneal dialysis.</p><p class=\"headingAnchor\" id=\"H2918960378\"><span class=\"h3\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with persistent, severe PH despite ligation of the AV fistula should be referred to centers with expertise in the management of PH for possible evaluation in trials of PH specific therapy [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=treatment-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">&quot;Treatment of pulmonary hypertension in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3868930531\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PH increases the risk of cardiovascular events and overall mortality. In various studies of hemodialysis patients, mortality was two- to threefold higher among those with PH [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/6,39-41\" class=\"abstract_t\">6,39-41</a>].</p><p>In one study of 211 hemodialysis patients, among whom 44 percent had PH, PH was independently associated with an increased risk for cardiovascular events [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Pulmonary artery pressures may normalize following kidney transplantation, even among patients who still have a functioning arteriovenous (AV) fistula [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/5,6,24\" class=\"abstract_t\">5,6,24</a>]. However, patients with PH require careful evaluation and optimal management prior to transplantation. Patients with severe PH may not be candidates for transplantation. (See <a href=\"topic.htm?path=evaluation-of-the-potential-renal-transplant-recipient#H119949756\" class=\"medical medical_review\">&quot;Evaluation of the potential renal transplant recipient&quot;, section on 'Pulmonary disease'</a>.)</p><p>Although rare, PH may predispose a patient to the development of a paradoxical embolus if a patent foreman ovale or atrial septal defect is present [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/43\" class=\"abstract_t\">43</a>]. There are several cases in the literature in which a devastating paradoxical embolus occurred after a thrombectomy of a dialysis access [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/44-48\" class=\"abstract_t\">44-48</a>]. The most frequent sites of paradoxical embolism are the extremities (50 percent) and the brain (40 percent), while the heart, spleen, and kidney are more rarely affected [<a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/49\" class=\"abstract_t\">49</a>].</p><p class=\"headingAnchor\" id=\"H2028289063\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-pulmonary-hypertension-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Pulmonary hypertension in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1042878597\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with end-stage renal disease (ESRD), particularly those on hemodialysis, are at increased risk for development of or worsening of pulmonary hypertension (PH). The increased risk is related in part to the arteriovenous (AV) access, although other factors related to ESRD also contribute. (See <a href=\"#H111099120\" class=\"local\">'Introduction'</a> above and <a href=\"#H4235246744\" class=\"local\">'Epidemiology and risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PH is related to noncompliance of the left ventricle with elevated pulmonary venous pressure, chronic volume overload and increased cardiac output, and an increase in pulmonary vascular resistance. The increased pulmonary resistance may be related to defects in endothelial dysfunction or neutrophil activation. (See <a href=\"#H686883394\" class=\"local\">'Pathogenesis in end-stage renal disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with pre-existing, symptomatic PH who are being considered for maintenance dialysis, we avoid AV access for hemodialysis, which may worsen PH. We prefer peritoneal dialysis when possible. Peritoneal dialysis obviates the need for AV access and provides daily ultrafiltration that may prevent worsening of symptoms with interdialytic volume overload.</p><p/><p class=\"bulletIndent1\">A tunneled catheter for hemodialysis is an alternative to peritoneal dialysis. Tunneled catheters are less likely to worsen PH but carry a long-term higher risk for infection compared with AV fistulas.</p><p/><p class=\"bulletIndent1\">Daily dialysis (home or in center) may provide a benefit because it minimizes volume accumulation. (See <a href=\"#H518583624\" class=\"local\">'Dialysis modality in preexisting PH'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients on chronic hemodialysis should be closely monitored for symptoms of PH. (See <a href=\"#H874504879\" class=\"local\">'Monitoring for PH'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Our approach to patients who develop or have worsening of symptoms of PH on dialysis is as follows (see <a href=\"#H3325684074\" class=\"local\">'Treatment of symptomatic patients'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>All patients should undergo aggressive ultrafiltration. We target the lowest dry weight that does not causing intra- or interdialytic hypotension or other symptoms. This may require changes in the dialysis prescription to provide longer or more frequent dialysis sessions in order to safely achieve a lower dry weight.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If symptoms persist despite aggressive ultrafiltration, we confirm the diagnosis of PH and, if present, the contribution of the AV fistula to PH. In patients with confirmed PH secondary to AV fistula, we ligate the AV fistula. We switch patients who are candidates to peritoneal dialysis. We place a tunneled catheter in patients who are not peritoneal dialysis candidates.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with persistent, severe PH despite ligation of the AV fistula should be referred to centers with expertise in the management of PH for possible evaluation in trials of PH-specific therapy. (See <a href=\"topic.htm?path=treatment-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">&quot;Treatment of pulmonary hypertension in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PH increases the risk of cardiovascular events and overall mortality. (See <a href=\"#H3868930531\" class=\"local\">'Prognosis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/1\" class=\"nounderline abstract_t\">Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34.</a></li><li class=\"breakAll\">Rich S (ed). Executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France, September 6-10, 1998, co-sponsored by The World Health Organization.</li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/3\" class=\"nounderline abstract_t\">Yigla M, Abassi Z, Reisner SA, Nakhoul F. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19:353.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/4\" class=\"nounderline abstract_t\">Abassi Z, Nakhoul F, Khankin E, et al. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 2006; 15:353.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/5\" class=\"nounderline abstract_t\">Nakhoul F, Yigla M, Gilman R, et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 2005; 20:1686.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/6\" class=\"nounderline abstract_t\">Yigla M, Nakhoul F, Sabag A, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123:1577.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/7\" class=\"nounderline abstract_t\">Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant 2012; 27:3908.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/8\" class=\"nounderline abstract_t\">Ramasubbu K, Deswal A, Herdejurgen C, et al. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. Int J Gen Med 2010; 3:279.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/9\" class=\"nounderline abstract_t\">Abedini M, Sadeghi M, Naini AE, et al. Pulmonary hypertension among patients on dialysis and kidney transplant recipients. Ren Fail 2013; 35:560.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/10\" class=\"nounderline abstract_t\">Kumbar L, Fein PA, Rafiq MA, et al. Pulmonary hypertension in peritoneal dialysis patients. Adv Perit Dial 2007; 23:127.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/11\" class=\"nounderline abstract_t\">Unal A, Sipahioglu M, Oguz F, et al. Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors. Perit Dial Int 2009; 29:191.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/12\" class=\"nounderline abstract_t\">Bozbas SS, Akcay S, Altin C, et al. Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc 2009; 41:2753.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/13\" class=\"nounderline abstract_t\">Etemadi J, Zolfaghari H, Firoozi R, et al. Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients. Rev Port Pneumol 2012; 18:10.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/14\" class=\"nounderline abstract_t\">Fabbian F, Cantelli S, Molino C, et al. Pulmonary hypertension in dialysis patients: a cross-sectional italian study. Int J Nephrol 2010; 2011:283475.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/15\" class=\"nounderline abstract_t\">Bolignano D, Rastelli S, Agarwal R, et al. Pulmonary hypertension in CKD. Am J Kidney Dis 2013; 61:612.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/16\" class=\"nounderline abstract_t\">Pabst S, Hammerstingl C, Hundt F, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One 2012; 7:e35310.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/17\" class=\"nounderline abstract_t\">Beigi AA, Sadeghi AM, Khosravi AR, et al. Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. J Vasc Access 2009; 10:160.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/18\" class=\"nounderline abstract_t\">Miller GA, Hwang WW. Challenges and management of high-flow arteriovenous fistulae. Semin Nephrol 2012; 32:545.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/19\" class=\"nounderline abstract_t\">Agarwal AK. Systemic Effects of Hemodialysis Access. Adv Chronic Kidney Dis 2015; 22:459.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/20\" class=\"nounderline abstract_t\">Vaes RH, Tordoir JH, Scheltinga MR. Systemic effects of a high-flow arteriovenous fistula for hemodialysis. J Vasc Access 2014; 15:163.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/21\" class=\"nounderline abstract_t\">Kosmadakis G, Aguilera D, Carceles O, et al. Pulmonary hypertension in dialysis patients. Ren Fail 2013; 35:514.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/22\" class=\"nounderline abstract_t\">Shoukat, Rehman IU, Sumera, et al. Pulmonary hypertension and leading factors in patients undergoing dialysis. J Coll Physicians Surg Pak 2014; 24:836.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/23\" class=\"nounderline abstract_t\">Clarkson MR, Giblin L, Brown A, et al. Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. Am J Kidney Dis 2002; 40:E8.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/24\" class=\"nounderline abstract_t\">Yigla M, Keidar Z, Safadi I, et al. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. Kidney Int 2004; 66:806.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/25\" class=\"nounderline abstract_t\">Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/26\" class=\"nounderline abstract_t\">Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol 2000; 13:96.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/27\" class=\"nounderline abstract_t\">Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. Am J Kidney Dis 2001; 38:S74.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/28\" class=\"nounderline abstract_t\">Amin M, Fawzy A, Hamid MA, Elhendy A. Pulmonary hypertension in patients with chronic renal failure: role of parathyroid hormone and pulmonary artery calcifications. Chest 2003; 124:2093.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/29\" class=\"nounderline abstract_t\">Zoccali C, Bode-B&ouml;ger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/30\" class=\"nounderline abstract_t\">Iwashima Y, Horio T, Takami Y, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/31\" class=\"nounderline abstract_t\">Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42:303.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/32\" class=\"nounderline abstract_t\">Kiykim AA, Horoz M, Ozcan T, et al. Pulmonary hypertension in hemodialysis patients without arteriovenous fistula: the effect of dialyzer composition. Ren Fail 2010; 32:1148.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/33\" class=\"nounderline abstract_t\">Dolmatch BL, Gray RJ, Horton KM. Will iatrogenic pulmonary embolization be our pulmonary embarrassment? Radiology 1994; 191:615.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/34\" class=\"nounderline abstract_t\">Smits HF, Van Rijk PP, Van Isselt JW, et al. Pulmonary embolism after thrombolysis of hemodialysis grafts. J Am Soc Nephrol 1997; 8:1458.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/35\" class=\"nounderline abstract_t\">Harp RJ, Stavropoulos SW, Wasserstein AG, Clark TW. Pulmonary hypertension among end-stage renal failure patients following hemodialysis access thrombectomy. Cardiovasc Intervent Radiol 2005; 28:17.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/36\" class=\"nounderline abstract_t\">Sakaguchi Y, Shoji T, Kawabata H, et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol 2011; 6:995.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/37\" class=\"nounderline abstract_t\">Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 2002; 13:729.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/38\" class=\"nounderline abstract_t\">Bay WH, Henry ML, Lazarus JM, et al. Predicting hemodialysis access failure with color flow Doppler ultrasound. Am J Nephrol 1998; 18:296.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/39\" class=\"nounderline abstract_t\">Acarturk G, Albayrak R, Melek M, et al. The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients. Int Urol Nephrol 2008; 40:509.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/40\" class=\"nounderline abstract_t\">Alkhouli M, Sandhu P, Boobes K, et al. Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease. Nefrologia 2015; 35:234.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/41\" class=\"nounderline abstract_t\">Selvaraj S, Shah SJ, Ommerborn MJ, et al. Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study. Circ Heart Fail 2017; 10.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/42\" class=\"nounderline abstract_t\">Reque J, Quiroga B, Ruiz C, et al. Pulmonary hypertension is an independent predictor of cardiovascular events and mortality in haemodialysis patients. Nephrology (Carlton) 2016; 21:321.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/43\" class=\"nounderline abstract_t\">Wu S, Ahmad I, Qayyum S, et al. Paradoxical embolism after declotting of hemodialysis fistulae/grafts in patients with patent foramen ovale. Clin J Am Soc Nephrol 2011; 6:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/44\" class=\"nounderline abstract_t\">Bentaarit B, Duval AM, Maraval A, et al. Paradoxical embolism following thromboaspiration of an arteriovenous fistula thrombosis: a case report. J Med Case Rep 2010; 4:345.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/45\" class=\"nounderline abstract_t\">Briefel GR, Regan F, Petronis JD. Cerebral embolism after mechanical thrombolysis of a clotted hemodialysis access. Am J Kidney Dis 1999; 34:341.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/46\" class=\"nounderline abstract_t\">Santos JP, Hamadeh Z, Ansari N. Cerebrovascular accident secondary to paradoxical embolism following arteriovenous graft thrombectomy. Case Rep Nephrol 2012; 2012:183730.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/47\" class=\"nounderline abstract_t\">Owens CA, Yaghmai B, Aletich V, et al. Fatal paradoxic embolism during percutaneous thrombolysis of a hemodialysis graft. AJR Am J Roentgenol 1998; 170:742.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/48\" class=\"nounderline abstract_t\">Pinard EA, Fazal S, Schussler JM. Catastrophic paradoxical embolus after hemodialysis access thrombectomy in a patient with a patent foramen ovale. Int Urol Nephrol 2013; 45:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-hypertension-in-hemodialysis-patients/abstract/49\" class=\"nounderline abstract_t\">Gill TJ, Campbell CC. Radial artery occlusion by a paradoxical embolism: a case report. J Hand Surg Am 1995; 20:406.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 112442 Version 3.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1042878597\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H111099120\" id=\"outline-link-H111099120\">INTRODUCTION</a></li><li><a href=\"#H3715598996\" id=\"outline-link-H3715598996\">DEFINITION AND CLASSIFICATION</a></li><li><a href=\"#H4235246744\" id=\"outline-link-H4235246744\">EPIDEMIOLOGY AND RISK FACTORS</a><ul><li><a href=\"#H2691105011\" id=\"outline-link-H2691105011\">Dialysis-specific risk factors</a></li></ul></li><li><a href=\"#H686883394\" id=\"outline-link-H686883394\">PATHOGENESIS IN END-STAGE RENAL DISEASE</a></li><li><a href=\"#H1861623073\" id=\"outline-link-H1861623073\">CLINICAL FEATURES</a></li><li><a href=\"#H2374946375\" id=\"outline-link-H2374946375\">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS IN DIALYSIS PATIENTS</a><ul><li><a href=\"#H1584569684\" id=\"outline-link-H1584569684\">Suspecting PH in patients with ESRD</a></li><li><a href=\"#H3747593179\" id=\"outline-link-H3747593179\">Diagnosis</a></li></ul></li><li><a href=\"#H372974248\" id=\"outline-link-H372974248\">MANAGEMENT</a><ul><li><a href=\"#H518583624\" id=\"outline-link-H518583624\">Dialysis modality in preexisting PH</a></li><li><a href=\"#H874504879\" id=\"outline-link-H874504879\">Monitoring for PH</a></li><li><a href=\"#H3325684074\" id=\"outline-link-H3325684074\">Treatment of symptomatic patients</a><ul><li><a href=\"#H3142051344\" id=\"outline-link-H3142051344\">- Dialysis management</a></li><li><a href=\"#H1580786084\" id=\"outline-link-H1580786084\">- Access management</a></li><li><a href=\"#H2918960378\" id=\"outline-link-H2918960378\">- Other therapies</a></li></ul></li></ul></li><li><a href=\"#H3868930531\" id=\"outline-link-H3868930531\">PROGNOSIS</a></li><li><a href=\"#H2028289063\" id=\"outline-link-H2028289063\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H1042878597\" id=\"outline-link-H1042878597\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEPH/112442|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/66348\" class=\"graphic graphic_table\">- Classification of pulmonary hypertension</a></li><li><a href=\"image.htm?imageKey=PULM/105764\" class=\"graphic graphic_table\">- Hemodynamics of pre-and post-capillary PH</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=arteriovenous-fistula-creation-for-hemodialysis-and-its-complications\" class=\"medical medical_review\">Arteriovenous fistula creation for hemodialysis and its complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=arteriovenous-graft-creation-for-hemodialysis-and-its-complications\" class=\"medical medical_review\">Arteriovenous graft creation for hemodialysis and its complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=choosing-a-modality-for-chronic-peritoneal-dialysis\" class=\"medical medical_review\">Choosing a modality for chronic peritoneal dialysis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-and-prognosis-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">Classification and prognosis of pulmonary hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">Clinical features and diagnosis of pulmonary hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dialysis-modality-and-patient-outcome\" class=\"medical medical_review\">Dialysis modality and patient outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-clinical-evaluation-and-diagnosis-of-pulmonary-veno-occlusive-disease-in-adults\" class=\"medical medical_review\">Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-heart-failure-caused-by-hemodialysis-arteriovenous-access\" class=\"medical medical_review\">Evaluation and management of heart failure caused by hemodialysis arteriovenous access</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-potential-renal-transplant-recipient\" class=\"medical medical_review\">Evaluation of the potential renal transplant recipient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intradialytic-hypotension-in-an-otherwise-stable-patient\" class=\"medical medical_review\">Intradialytic hypotension in an otherwise stable patient</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-chronic-hemodialysis-vascular-access\" class=\"medical medical_review\">Overview of chronic hemodialysis vascular access</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-arterial-hypertension-associated-with-human-immunodeficiency-virus\" class=\"medical medical_review\">Pulmonary arterial hypertension associated with human immunodeficiency virus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-artery-catheterization-interpretation-of-hemodynamic-values-and-waveforms-in-adults\" class=\"medical medical_review\">Pulmonary artery catheterization: Interpretation of hemodynamic values and waveforms in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-hypertension-due-to-lung-disease-and-or-hypoxemia-group-3-pulmonary-hypertension-epidemiology-pathogenesis-and-diagnostic-evaluation-in-adults\" class=\"medical medical_review\">Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-hypertension-in-patients-with-left-heart-failure\" class=\"medical medical_review\">Pulmonary hypertension in patients with left heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-pulmonary-hypertension-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Pulmonary hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-epidemiology-and-pathogenesis-of-pulmonary-arterial-hypertension-group-1\" class=\"medical medical_review\">The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-hypertension-in-adults\" class=\"medical medical_review\">Treatment of pulmonary hypertension in adults</a></li></ul></div></div>","javascript":null}